

PHARMACEUTICAL 2017



PIERIS PHARMACEUTICALS INC. Rank 140 of 292







PHARMACEUTICAL 2017

PIERIS PHARMACEUTICALS INC. Rank 140 of 292



The relative strengths and weaknesses of PIERIS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PIERIS PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of PIERIS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 88% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	32,673
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,380
Liabilities, Non-Current	47
Other Assets	126
Other Compr. Net Income	-229
Other Expenses	162
Other Liabilities	1,409
Other Net Income	122
Other Revenues	5,831
Property and Equipment	2,264
Research and Development	19,699
Selling, General and Administrative Expense	8,891

Output Variable	Value in 1000 USD
Assets	35,063
Liabilities	9,836
Expenses	28,752
Revenues	5,831
Stockholders Equity	25,227
Net Income	-22,799
Comprehensive Net Income	-22,914
Economic Capital Ratio	91%

